Metagen Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 2 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
About Metagen Pharmaceutical
Metagen Pharmaceutical Private Limited (MPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 21 June 2022 (Two years and seven months 13 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Pimple, Amey Patil, Kiran More, and Three other members serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299MH2022PTC385017
-
Company No.
385017
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Jun 2022
-
Date of AGM
22 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Metagen Pharmaceutical?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Pimple
|
Director | 21-Jun-2022 | Current |
|
Amey Patil
|
Director | 21-Jun-2022 | Current |
|
Kiran More
|
Director | 21-Jun-2022 | Current |
|
Sagar Shinde
|
Director | 07-Sep-2022 | Current |
|
Dhawal Bhanushali
|
Director | 02-Jun-2023 | Current |
|
Janvi Patil
|
Director | 20-May-2024 | Current |
Financial Performance of Metagen Pharmaceutical.
Metagen Pharmaceutical Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Metagen Pharmaceutical?
In 2023, Metagen Pharmaceutical had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Atgenx Pharmaceutical India Private LimitedAtul Pimple is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Metagen Pharmaceutical?
Metagen Pharmaceutical has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Metagen Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Metagen Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
